Production (Stage)
Lipocine Inc.
LPCN
$3.17
$0.0481.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.77% | 1,514.89% | -- | -- | 13,749.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -98.77% | 1,514.89% | -- | -- | 13,749.45% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -98.77% | 1,514.89% | -- | -- | 13,749.45% |
| SG&A Expenses | -28.76% | -23.05% | 0.25% | 4.65% | 22.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.30% | -30.74% | -32.92% | -14.50% | 0.02% |
| Operating Income | -164.86% | 159.59% | 62.65% | 16.76% | 174.28% |
| Income Before Tax | -153.07% | 178.11% | 66.64% | 13.54% | 190.80% |
| Income Tax Expenses | 0.00% | -100.00% | -- | -- | 0.00% |
| Earnings from Continuing Operations | -153.08% | 178.09% | 66.64% | 13.53% | 190.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -153.08% | 178.09% | 66.64% | 13.53% | 190.79% |
| EBIT | -164.86% | 159.59% | 62.65% | 16.76% | 174.28% |
| EBITDA | -164.21% | 160.38% | 62.73% | 16.81% | 174.55% |
| EPS Basic | -152.75% | 177.61% | 66.99% | 15.30% | 189.41% |
| Normalized Basic EPS | -152.75% | 177.67% | 66.99% | 15.32% | 189.40% |
| EPS Diluted | -152.95% | 172.52% | 65.32% | 15.94% | 187.19% |
| Normalized Diluted EPS | -153.16% | 173.08% | 66.99% | 15.32% | 188.70% |
| Average Basic Shares Outstanding | 0.62% | 0.60% | 1.05% | 2.08% | 1.55% |
| Average Diluted Shares Outstanding | -0.17% | 6.89% | 1.05% | 2.08% | 2.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |